20
8/3/2019 INFLAMATORNE BOLESTI http://slidepdf.com/reader/full/inflamatorne-bolesti 1/20 284 PDQ ORAL DISEASE Inflammatory Diseases  Angioedema Etiology Usually triggered by ingested antigens (eg, shellfish, nuts, fruits, medications) Mechanism associated with immunoglobulin E (IgE)-mediated mast cell degranulation with subsequent histamine release Drug reactions resulting in release of inflammatory mediators (bradykinin) Some cases have a genetic basis: C1 esterase inhibitor deficien- cy or inhibitor dysfunction (autosomal recessive) May be correlated with disease states characterized by the presence of circulating immune complexes Clinical Presentation Soft, diffuse, painless swelling of face, lips, and neck Overlying skin and oral mucosa appear noninflamed Mucosa may become secondarily erythematous, ulcerative, or, rarely, vesicular Usually short-lived (24–48 hours) Diagnosis Nonspecific histology Correlation of history and clinical findings Differential Diagnosis Trauma (physical, cold) Cellulitis Vascular malformation Acute contact stomatitis Melkersson-Rosenthal syndrome (early stages) Orofacial granulomatosis (early stages) Treatment Elimination of possible etiologic/precipitating factor(s) Antihistamines, corticosteroids, adrenaline

INFLAMATORNE BOLESTI

Embed Size (px)

Citation preview

Page 1: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 1/20

284 PDQ ORAL DISEASE

Inflammatory Diseases

 Angioedema

Etiology

• Usually triggered by ingested antigens (eg, shellfish, nuts,

fruits, medications)

• Mechanism associated with immunoglobulin E (IgE)-mediated

mast cell degranulation with subsequent histamine release

• Drug reactions resulting in release of inflammatory mediators

(bradykinin)

• Some cases have a genetic basis: C1 esterase inhibitor deficien-

cy or inhibitor dysfunction (autosomal recessive)

• May be correlated with disease states characterized by the

presence of circulating immune complexes

Clinical Presentation

• Soft, diffuse, painless swelling of face, lips, and neck

• Overlying skin and oral mucosa appear noninflamed

• Mucosa may become secondarily erythematous, ulcerative, or,

rarely, vesicular

• Usually short-lived (24–48 hours)

Diagnosis

• Nonspecific histology

• Correlation of history and clinical findings

Differential Diagnosis

• Trauma (physical, cold)

• Cellulitis

• Vascular malformation

• Acute contact stomatitis

• Melkersson-Rosenthal syndrome (early stages)

• Orofacial granulomatosis (early stages)

Treatment

• Elimination of possible etiologic/precipitating factor(s)

• Antihistamines, corticosteroids, adrenaline

Page 2: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 2/20

Inflammatory Diseases 285

Prognosis

• Good to excellent

Page 3: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 3/20

286 PDQ ORAL DISEASE

Cheilitis Granulomatosa

Etiology

• Isolated, idiopathic, and chronic lip enlargement

• May be an incompletely expressed or oligosymptomatic form

of Melkersson-Rosenthal syndrome

Clinical Presentation

• One or both lips may be diffusely enlarged and nontender.• Episodic swelling initially, with progression to a persistent

enlargement

• Less often, superficial labial exfoliation or surface

weeping/crusting may be noted.

• Lip swelling may herald similar changes of the gingiva, buccal

mucosa, or palate.

• May be associated with Crohn’s disease, sarcoidosis, contactsensitivity, dental abscesses

Microscopic Findings

• Demonstrates noncaseating epithelioid granulomas

• Absence of organisms

Diagnosis

• History of intermittent to persistent asymptomatic lip swelling

• Characteristic appearance

• Lip or soft tissue biopsy (involved gingiva)

• Rule out sarcoidosis (chest radiograph, serum angiotensin-

converting enzyme levels)

• Patch testing for contact allergens

• Dental radiographs to rule out asymptomatic periapical

pathology

Differential Diagnosis

• Angioedema

• Cellulitis/erysipeloid reaction

• Sarcoidosis

• Crohn’s disease

• Melkersson-Rosenthal syndrome

• Cheilitis glandularis

• Contact stomatitis

Page 4: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 4/20

Inflammatory Diseases 287

Treatment

• Local intralesional triamcinolone injections under local anes-

thesia• 5 to 10 mg total dose in depot fashion every 3 to 4 weeks to

achieve response

• Local treatment may be coupled with an initial systemic course

of glucocorticoids.

• Clofazimine 100 mg daily for 60 days with reduction to a

maintenance dose of 30 mg on alternate days

• Metronidazole may also be effective at 250 mg three timesdaily for 1 month. This may be coupled with intralesional cor-

ticosteroid placement.

• Dapsone may be effective (as per dermatitis herpetiformis dos-

ing)

• Surgical reduction (cheiloplasty) may be necessary.

Prognosis• Guarded

• Must remain aware of possible neurologic manifestations, oph-

thalmologic involvement, psychological effects

Page 5: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 5/20

288 PDQ ORAL DISEASE

Drug-Induced Stomatitis

(Stomatitis Medicamentosa)

Etiology

• Oral changes found in approximately 5% of those with cuta-

neous reaction to drugs

• Mucosal alterations may result from the following:

• Myelosuppression

• Direct cytotoxic or cytostatic effect(s) on dividing epithelialcells

• Xerostomic effects

• Alterations of oral microbial flora

Clinical Presentation

• Painful, erythematous, erosive, or ulcerative lesions

• Nonkeratinized locations often affected initially• Fixed form of drug-associated eruptions relatively uncommon

intraorally

• Pseudomembranous necrotic surface may be noted

Diagnosis

• History

• Clinical appearance

Differential Diagnosis

• Chemical or thermal burn

• Erosive lichen planus

• Pemphigus vulgaris

• Mucous membrane (cicatricial) pemphigoid

• Erythema multiforme

• Acute herpetic gingivostomatitis

• Candidiasis

Treatment

• Identification and withdrawal of offending drug

• Symptomatic management including topical preparations

(see “Therapeutics” section)

Page 6: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 6/20

Inflammatory Diseases 289

• Systemic corticosteroids if mucosal reaction is not related to

antineoplastic treatment

Prognosis

• Generally excellent

Page 7: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 7/20

290 PDQ ORAL DISEASE

Garré’s Osteomyelitis

Etiology

• Chronic, low-grade, dentoalveolar infection

• Resultant bony inflammation extends to the periosteum, pro-

ducing a reduplication of the cortex (“onion skin” effect).

Clinical Presentation

• Usually an asymptomatic, unilateral, mandibular, bony hardasymmetry

• Limited to children and young adults

Radiographic Findings

• Medullary mottling with (lucent and opaque) ill-defined margins

• Periosteal-cortical expansion

• Occlusal radiograph shows concentric or parallel layering of cortex

Diagnosis

• Carious mandibular tooth, usually first permanent molar

• Radiographic features

• Biopsy results showing periosteal osteoblastic reaction, mini-

mally inflamed fibrous marrow

Differential Diagnosis

• Ewing’s sarcoma

• Langerhans cell disease (histiocytosis X)

• Osteosarcoma

• Fibro-osseous lesion

• Metastatic disease

Treatment

• Elimination of the infected focus (carious tooth to be extracted

or filled)

• Antibiotic administration early in treatment phase

Prognosis

• Good

Page 8: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 8/20

Inflammatory Diseases 291

Page 9: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 9/20

292 PDQ ORAL DISEASE

Gingivitis

Etiology

• Variable

• Most are microbiologic or plaque associated (simple marginal

gingivitis).

• Some are modified by hormonal changes, such as those in

pregnancy (pregnancy gingivitis).

• Fusospirochetal gingivitis plus poor oral hygiene and poor nutri-tion are associated with acute necrotizing ulcerative gingivitis.

• Rarely, some forms are associated with contact allergy (“plasma

cell gingivitis”).

Clinical Presentation

• Dependent on etiology, as follows:

• Plaque associated: marginal inflammation to moregeneralized erythema and blunting of interdental papillae

with rolled margins

• Hormonally related: diffuse erythema and hyperplasia

• Fusospirochetal: necrotic, blunted, ulcerated interdental

papillae with spontaneous bleeding; foul odor

• Allergy based: hyperplastic and bright red, granular to

velvety surface alteration

Diagnosis

• Identification of cause

• Patch testing for contact allergens

Differential Diagnosis

• Acquired immunodeficiency syndrome–associated periodontaldisease

• Oral lichen planus

• Mucous membrane (cicatricial) pemphigoid

• Acute herpetic gingivostomatitis

• Pemphigus vulgaris

Page 10: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 10/20

Inflammatory Diseases 293

Treatment

• Local débridement and chlorhexidine rinses in cases of bacterial

origin• Reduction of hormonal dosage

• Elimination of allergen

Prognosis

• Excellent

Page 11: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 11/20

294 PDQ ORAL DISEASE

Median Rhomboid Glossitis

Etiology

• A benign, inflammatory condition

• Often related to yeast colonization (erythematous candidiasis)

• Inflammatory process noted in response to overlying Candida

population

• Exact mechanism is unclear

Clinical Presentation

• Well-defined, asymptomatic erythematous patch on dorsum of 

tongue

• Paramedian erythema, usually with focal atrophy of filiform

papillae

• Chronic forms may become multinodular.

• Rarely may be hyperkeratotic• May be mistaken for a benign or malignant tumor

Microscopic Findings

• Papillary, atrophic or hyperplastic epithelium

• Candidal colonization of surface

• Heavy, chronic inflammatory infiltrate

Diagnosis

• Clinical appearance, location

Treatment

• Topical and/or brief course of systemic antifungal therapy

(optional)

• Observation

Prognosis

• Excellent

Page 12: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 12/20

Inflammatory Diseases 295

Page 13: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 13/20

296 PDQ ORAL DISEASE

Osteomyelitis

Etiology

• An acute or chronic inflammatory process within the

medullary space or along the cortical surface of bone

• Usually due to extension of a periapical abscess

• Other common causes include physical trauma (fracture) or

bacteremia.

• Most common organisms include staphylococci and streptococci

Clinical Presentation

• Pain, swelling, fever, lymphadenitis

• Sequestrum formation

• Lower lip paresthesia, occasionally with acute disease in

mandible

• Associated soft tissue swelling

Radiographic Findings

• Acute phase may be unremarkable

• Ill-defined, patchy radiolucency (“moth eaten”)

Diagnosis

• Presentation and radiographic findings

• Microscopic evidence of intrabony inflammation, marrow

fibrosis, osteoclastic resorption, reduced osteoblastic activity,

nonviable bone

Differential Diagnosis

• Osteosarcoma

• Local extension of malignant tumor

• Metastatic tumor• Osteoradionecrosis

Treatment

• Drainage and antibiotics for acute disease

• Débridement, sequestrectomy, antibiotics for chronic disease

• Reconstruction if necessary after disease is resolved

Prognosis

• Good

Page 14: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 14/20

Inflammatory Diseases 297

Page 15: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 15/20

298 PDQ ORAL DISEASE

Osteoradionecrosis

Etiology

• A serious complication of tumoricidal doses of radiation to

the head and neck, usually > 60 Gy (6,000 rads)

• Radiation produces damage to the microvasculature, permit-

ting a hypoxic state, which, in turn, leads to a hypocellular

bony environment.

• Minor damage to the irradiated bone produces a nonhealingwound, forming dead bone—necrosis.

Clinical Presentation

• Usually affects the mandible

• Bone pain

• Exposed necrotic bone within radiation portal

• External fistula formation• Pathologic fracture

Radiographic Findings

• Irregular zones of mixed radiopacity and radiolucency

• Separation of nonvital bone (sequestrum) from remaining

viable bone

Diagnosis

• Radiographic and clinical features

• Biopsy results show nonvital bone.

Differential Diagnosis

• Metastatic tumor

• Locally recurrent tumor• Osteomyelitis

• Osteosarcoma

• Radiation-induced sarcoma

Treatment

• After biopsy, débridement of bone preceded and followed by

hyperbaric oxygen therapy• If necessary, resection and reconstruction

Page 16: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 16/20

Inflammatory Diseases 299

• Necessary tooth extraction and elimination of focal infection

within radiation portal 21 days prior to treatment

• Excellent preventive dental care

Prognosis

• Guarded

Page 17: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 17/20

 300 PDQ ORAL DISEASE

Periapical Granuloma

Etiology

• A mass of inflamed granulation tissue

• Forms secondary to pulp necrosis of the associated tooth

• May develop following periapical abscess formation or may

form as pulpal death eventuates without abscess precursor

Clinical Presentation• Usually asymptomatic

• With acute exacerbation, pain and sensitivity develop.

• Tenderness at root apex on palpation

• Pain on biting or percussion of tooth

Radiographic Findings

• Radiolucency at apex of tooth• Size ranges up to 1 to 2 cm in diameter

• Root resorption not uncommon

Diagnosis

• Radiographic features

• Demonstration of nonvital pulpal component

Differential Diagnosis

• Periapical cemental dysplasia

• Periapical cyst

Treatment

• Conventional endodontic therapy

• Apical curettage/root end amputation if above measures fail• Extraction of involved tooth

Prognosis

• Excellent

Page 18: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 18/20

Inflammatory Diseases 301

Page 19: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 19/20

 302 PDQ ORAL DISEASE

Sarcoidosis

Etiology

• Unknown; granulomatous disease process

• May represent a systemic response to a single provoking agent;

mycobacteria has been suggested but not proven

• Possible role of genetic factors coupled with disordered reac-

tions to foreign antigens

Clinical Presentation

• Mucocutaneous

• Red to brown nodules/plaques with erythema nodosum

features

• Minor salivary glands of the lips and palate may be involved.

• Erythematous, hyperplastic gingiva

• Salivary/lacrimal• Parotid, submandibular, and lacrimal glands may be

enlarged.

• Multiple organ systems, such as the following, may be involved:

• Particularly the lung, but also liver, endocrine glands, the

heart, and the reticuloendothelial and musculoskeletal

systems

• Heerfordt’s syndrome may be related to sarcoidosis (uveitis,parotid gland enlargement, fever, cranial nerve palsies).

Diagnosis

• Demonstration of sarcoidal (noncaseating epitheloid) granulo-

mas in at least two organ systems

• Elevated serum angiotensin-converting enzyme levels are

usually present.• Over 90% of cases have abnormal chest radiograph.

• Other causes of granulomatous inflammation must be ruled out.

Differential Diagnosis

• Tuberculosis

• Lymphoma (non-Hodgkin’s, Hodgkin’s)

• Deep fungal infection• Crohn’s disease

Page 20: INFLAMATORNE BOLESTI

8/3/2019 INFLAMATORNE BOLESTI

http://slidepdf.com/reader/full/inflamatorne-bolesti 20/20

Inflammatory Diseases 303

Treatment

• Corticosteroids, if symptoms demand

• Severe or unresponsive cases: methotrexate• Cutaneous lesions only: hydroxychloroquine

• Intralesional corticosteroids

Prognosis

• Generally good